CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

计划入组 12 人 · 首次发布于 2023 年 9 月 11 日

Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial

计划入组 15 人 · 首次发布于 2024 年 10 月 2 日

Detection of Enterovirus Genotypes by CRISPR Technology

首次发布于 2020 年 9 月 2 日

DMPK CRISPR/Cas13-gene therapy (HuidaGene Therapeutics)

CRISPR-Cas13d(CasRx)

DMPK CRISPR/Cas13-gene therapy (AAV, myotonic dystrophy type 1)

CRISPR Therapeutics

United States

CRISPR Therapeutics, Inc.

United States

Editas Medicine

United States

FDA Clears HuidaGene's CRISPR/Cas13 RNA-Editing Therapy HG202 for nAMD

HuidaGene's CRISPR/Cas13 RNA-Editing Therapy HG202 Cleared for US Trial in Macular Degeneration

FDA Approves First CRISPR-Cas13 RNA Editing Trial for Wet Age-Related Macular Degeneration